Weekly Digest – November 2025 Weekly Digest – November 2025 10 November 2025: Arrivent Biopharma received FDA IND clearance for ARR-217, a CDH-17 targeted ADC ArriVent highlighted steady progress across its pipeline, including FDA IND clearance for ARR-217, a CDH17-targeted ADC […]
Weekly Digest – November 2025 Weekly Digest – November 2025 10 November 2025: Celltrion’s solid tumor ADC drug candidate CT-P73 has received approval for phase 1 clinical trials in Korea Celltrion has moved its new ADC candidate CT-P73 into domestic […]
Weekly Digest – November 2025 Weekly Digest – November 2025 07 November 2025: BioAtla’s Mecbotamab Vedotin (Mec-V), an AXL-targeting ADC, demonstrates a median overall survival (OS) of 21.5 months in subtypes of refractory soft tissue sarcomas BioAtla shared new Phase 2 data showing that its AXL-targeting […]
Weekly Digest – November 2025 Weekly Digest – November 2025 13 November 2025: Day One to acquire Mersana Therapeutics to advance mission to bring new medicines to people of all ages with life-threatening diseases Day One Biopharmaceuticals announced a major step […]
Weekly Digest – November 2025 Weekly Digest – November 2025 06 November 2025: Sutro Biopharma announces FDA clearance for IND application of STRO-004 and upcoming virtual R&D day Sutro Biopharma received FDA IND clearance for STRO-004, a potential best-in-class Tissue […]
Weekly Digest – November 2025 Weekly Digest – November 2025 04 November 2025: MSD enters into research and development funding agreement with Blackstone Life Sciences for Sacituzumab tirumotecan (sac-TMT) MSD announced a $700 million strategic financing agreement with Blackstone Life […]
Weekly Digest – November 2025 Weekly Digest – November 2025 05 November 2025: ABL Bio subsidiary Neok Bio officially launches in the US, accelerating development of dual antibody ADCs ABL Bio officially launched its U.S.-based subsidiary Neok Bio, focused on […]
Weekly Digest – November 2025 Weekly Digest – November 2025 31 October 2025: Mycenax and RIN sign license agreement to advance ADC development using RIN’s proprietary linker technology Mycenax Biotech Inc., a Taiwan-based biologics CDMO, entered into a License Agreement […]
Weekly Digest – November 2025 Weekly Digest – November 2025 31 October 2025: IntoCell and Xcellon Biologics partner to expand access to next-generation ADC technologies Xcellon Biologics, a leading ADC-focused CDMO, has entered into a partnership with IntoCell Inc. to […]
Weekly Digest – November 2025 Weekly Digest – November 2025 31 October 2025: Ajinomoto Inc enters licensing agreement with Astellas Pharma for biopharmaceutical development and manufacturing technology Ajinomoto Co., Inc. has entered into a licensing agreement with Astellas Pharma Inc. […]
